Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42732   clinical trials with a EudraCT protocol, of which   7035   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Multicenter Open-Label Phase 1b/2 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Summary
    EudraCT number
    2013-004341-17
    Trial protocol
    BE   GB  
    Global end of trial date
    17 Dec 2020

    Results information
    Results version number
    v1(current)
    This version publication date
    16 Dec 2021
    First version publication date
    16 Dec 2021
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    PCYC-1123-CA
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02077166
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    AbbVie Deutschland GmbH & Co. KG
    Sponsor organisation address
    AbbVie House, Vanwall Business Park, Vanwall Road,, Maidenhead, Berkshire, United Kingdom, SL6 4UB
    Public contact
    Global Medical Services, AbbVie, 001 8006339110 , abbvieclinicaltrials@abbvie.com
    Scientific contact
    Global Medical Services, AbbVie, 001 8006339110 , abbvieclinicaltrials@abbvie.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    17 Dec 2020
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    17 Dec 2020
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    Phase 1b: • To determine the maximum tolerated doses (MTD) and/or the recommended Phase 2 (RP2) dose of ibrutinib in combination with lenalidomide and rituximab by dose escalation of lenalidomide in subjects with relapsed or refractory DLBCL • To determine the safety and tolerability of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed or refractory DLBCL by dose escalating lenalidomide Phase 2: • To evaluate the efficacy of ibrutinib in combination with lenalidomide and rituximab by assessing the overall response rate (ORR) in subjects with relapsed or refractory non-GCB DLBCL
    Protection of trial subjects
    The Investigator or designee (designee must be listed on the Delegation of Authority log), must explain in terms understandable to the subject the purpose and nature of the study, study procedures, anticipated benefits, potential risks, possible adverse events (AEs), and any discomfort participation in the study may entail. This process must be documented in the subject’s source record. Each subject must provide a signed and dated informed consent form (ICF) before any study-related (nonstandard of care) activities are performed.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    13 Mar 2013
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Belgium: 10
    Country: Number of subjects enrolled
    Germany: 2
    Country: Number of subjects enrolled
    United Kingdom: 43
    Country: Number of subjects enrolled
    United States: 83
    Worldwide total number of subjects
    138
    EEA total number of subjects
    12
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    70
    From 65 to 84 years
    65
    85 years and over
    3

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    All participants had relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In the Phase 1b portion of the study, all subtypes of DLBCL and participants with transformed disease were enrolled. In the Phase 2 portion of the study, only participants with non-germinal-center B-cell-like (non-GCB) DLBCL were enrolled.

    Pre-assignment
    Screening details
    In the Phase 1b portion of this study, different dose levels of lenalidomide were explored, and dose escalation of lenalidomide followed the 3+3+3 dose escalation schema. Participants remained on study until disease progression or unacceptable toxicity. "Reason for non-completion" rows below display the primary reason for exiting the study.

    Pre-assignment period milestones
    Number of subjects started
    138
    Number of subjects completed
    134

    Pre-assignment subject non-completion reasons
    Reason: Number of subjects
    Did not receive any treatment: 4
    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)
    Arm description
    Ibrutinib 560 mg administered orally (PO) once daily (QD) beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered intravenously (IV) on Day 1 of each 28-day cycle for 6 cycles.
    Arm type
    Experimental

    Investigational medicinal product name
    ibrutinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Ibrutinib was administered orally daily beginning Cycle 1 Day 1.

    Investigational medicinal product name
    lenalidomide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Lenalidomide will be administered orally daily on Days 1-21 of each 28-day cycle.

    Investigational medicinal product name
    rituximab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Rituximab was administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Arm title
    Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)
    Arm description
    De-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 10 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
    Arm type
    Experimental

    Investigational medicinal product name
    ibrutinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Ibrutinib was administered orally daily beginning Cycle 1 Day 1.

    Investigational medicinal product name
    lenalidomide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Lenalidomide will be administered orally daily on Days 1-21 of each 28-day cycle.

    Investigational medicinal product name
    rituximab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Rituximab was administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Arm title
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)
    Arm description
    Re-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
    Arm type
    Experimental

    Investigational medicinal product name
    ibrutinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Ibrutinib was administered orally daily beginning Cycle 1 Day 1.

    Investigational medicinal product name
    lenalidomide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Lenalidomide will be administered orally daily on Days 1-21 of each 28-day cycle.

    Investigational medicinal product name
    rituximab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Rituximab was administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Arm title
    Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)
    Arm description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
    Arm type
    Experimental

    Investigational medicinal product name
    ibrutinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Ibrutinib was administered orally daily beginning Cycle 1 Day 1.

    Investigational medicinal product name
    lenalidomide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Lenalidomide will be administered orally daily on Days 1-21 of each 28-day cycle.

    Investigational medicinal product name
    rituximab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Rituximab was administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Arm title
    Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)
    Arm description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
    Arm type
    Experimental

    Investigational medicinal product name
    ibrutinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Ibrutinib was administered orally daily beginning Cycle 1 Day 1.

    Investigational medicinal product name
    lenalidomide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Lenalidomide will be administered orally daily on Days 1-21 of each 28-day cycle.

    Investigational medicinal product name
    rituximab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Rituximab was administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Arm title
    Phase 2: Enrolled at Lenalidomide Dose 20 mg
    Arm description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
    Arm type
    Experimental

    Investigational medicinal product name
    ibrutinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Ibrutinib was administered orally daily beginning Cycle 1 Day 1.

    Investigational medicinal product name
    lenalidomide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Lenalidomide will be administered orally daily on Days 1-21 of each 28-day cycle.

    Investigational medicinal product name
    rituximab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Rituximab was administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Arm title
    Phase 2: Enrolled at Lenalidomide Dose 25 mg
    Arm description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.
    Arm type
    Experimental

    Investigational medicinal product name
    ibrutinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Ibrutinib was administered orally daily beginning Cycle 1 Day 1.

    Investigational medicinal product name
    lenalidomide
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule, hard
    Routes of administration
    Oral use
    Dosage and administration details
    Lenalidomide will be administered orally daily on Days 1-21 of each 28-day cycle.

    Investigational medicinal product name
    rituximab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Rituximab was administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Number of subjects in period 1 [1]
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) Phase 2: Enrolled at Lenalidomide Dose 20 mg Phase 2: Enrolled at Lenalidomide Dose 25 mg
    Started
    12
    7
    9
    9
    8
    55
    34
    Completed
    0
    0
    0
    0
    0
    0
    0
    Not completed
    12
    7
    9
    9
    8
    55
    34
         Death
    6
    7
    5
    6
    4
    32
    22
         Study Closure by Sponsor
    3
    -
    2
    2
    2
    12
    4
         Other, Not Specified
    -
    -
    1
    -
    1
    7
    8
         Consent withdrawn by subject
    3
    -
    1
    1
    1
    3
    -
         Lost to follow-up
    -
    -
    -
    -
    -
    1
    -
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: A total of 138 participants enrolled in the study; however, 4 participants exited the study without receiving any treatment, and are not presented in any data table.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)
    Reporting group description
    Ibrutinib 560 mg administered orally (PO) once daily (QD) beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered intravenously (IV) on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)
    Reporting group description
    De-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 10 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)
    Reporting group description
    Re-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 2: Enrolled at Lenalidomide Dose 20 mg
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 2: Enrolled at Lenalidomide Dose 25 mg
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group values
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) Phase 2: Enrolled at Lenalidomide Dose 20 mg Phase 2: Enrolled at Lenalidomide Dose 25 mg Total
    Number of subjects
    12 7 9 9 8 55 34 134
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    66.3 ± 13.13 58.4 ± 7.63 65.3 ± 13.44 66.0 ± 8.63 62.9 ± 14.23 63.1 ± 11.75 64.9 ± 12.52 -
    Gender categorical
    Units: Subjects
        Female
    4 3 5 5 3 23 14 57
        Male
    8 4 4 4 5 32 20 77
    Ethnicity
    Units: Subjects
        Hispanic or Latino
    1 3 1 0 0 0 5 10
        Not Hispanic or Latino
    11 4 8 9 8 55 29 124
    Race
    Units: Subjects
        Asian
    0 0 0 0 0 1 2 3
        Black or African American
    1 1 1 0 1 2 1 7
        White
    11 5 8 9 7 51 30 121
        Multiple Races
    0 0 0 0 0 0 1 1
        Declined to Answer/ Unknown
    0 1 0 0 0 1 0 2

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)
    Reporting group description
    Ibrutinib 560 mg administered orally (PO) once daily (QD) beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered intravenously (IV) on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)
    Reporting group description
    De-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 10 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)
    Reporting group description
    Re-escalation cohort: Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 2: Enrolled at Lenalidomide Dose 20 mg
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 2: Enrolled at Lenalidomide Dose 25 mg
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Subject analysis set title
    All Phase 1b Participants
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 10, 15, 20, or 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Subject analysis set title
    Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg
    Subject analysis set type
    Full analysis
    Subject analysis set description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 or 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

    Close Top of page
    End point title
    Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) [1]
    End point description
    The dose levels of lenalidomide were explored, and dose escalation of lenalidomide followed the 3+3+3 dose escalation schema. A Dose Level Review Committee evaluated safety data following completion of each dose observation period of the Phase 1b portion. All-Treated Analysis Population (Phase 1b): participants who received any dose of study drug(s).
    End point type
    Primary
    End point timeframe
    Estimated median time on study in Phase 1b was 59.6 months.
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Descriptive statistics are presented per protocol.
    End point values
    All Phase 1b Participants
    Number of subjects analysed
    45
    Units: mg
        number (not applicable)
    20
    No statistical analyses for this end point

    Primary: Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuations Due to TEAEs

    Close Top of page
    End point title
    Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and Discontinuations Due to TEAEs [2] [3]
    End point description
    An adverse event (AE) is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization > 24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. AEs that started or worsened during the treatment-emergent period and all possibly related or related AEs were considered TEAEs. Related events were those that were considered possibly related or related to study drug per investigator's judgment. Events were graded per the national Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03: Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life-threatening; grade 5=death. All-Treated Analysis Population (Phase 1).
    End point type
    Primary
    End point timeframe
    From first dose of study drug up to 30 days after last dose of study drug. Phase 1b median duration of ibrutinib exposure was 4.4 months; median duration of lenalidomide exposure was 4.4 months; median total number of doses of rituximab received was 4.0.
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Descriptive statistics are presented per protocol.
    [3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Phase 2 data are presented as a separate endpoint.
    End point values
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)
    Number of subjects analysed
    12
    7
    9
    9
    8
    Units: participants
        TEAE
    12
    7
    9
    9
    8
        Grade >=3 TEAE
    11
    6
    9
    9
    7
        Study Drug-Related TEAE
    12
    5
    9
    8
    8
        Grade >=3 Study Drug-Related TEAE
    10
    3
    8
    7
    7
        Ibrutinib-Related TEAE
    12
    5
    9
    8
    8
        Grade >=3 Ibrutinib-Related TEAE
    10
    3
    7
    7
    6
        Lenalidomide-Related TEAE
    12
    5
    9
    8
    8
        Grade >=3 Lenalidomide-Related TEAE
    9
    3
    8
    7
    6
        Rituximab-Related TEAE
    6
    4
    7
    6
    7
        Grade >= 3 Rituximab-Related TEAE
    1
    2
    7
    5
    3
        TEAE Leading to Dose Reduction of Any Study Drug
    4
    0
    4
    4
    5
        TEAE Leading to Dose Reduction of Ibrutinib
    3
    0
    4
    3
    3
        TEAE Leading to Dose Reduction of Lenalidomide
    2
    0
    3
    4
    4
        TEAE Leading to Dose Delay of Any Study Drug
    6
    4
    7
    8
    8
        TEAE Leading to Dose Delay of Ibrutinib
    6
    4
    7
    8
    8
        TEAE Leading to Dose Delay of Lenalidomide
    6
    3
    7
    7
    8
        TEAE Leading to Dose Delay of Rituximab
    4
    1
    6
    4
    4
        TEAE Leading to Discontinuation of Any Study Drug
    4
    2
    3
    2
    1
        TEAE Leading to Discontinuation of Ibrutinib Dose
    4
    2
    3
    2
    1
        TEAE Leading to Discontinuation of Lenalid. Dose
    4
    2
    3
    2
    1
        TEAE Leading to Discontinuation of Rituximab Dose
    3
    2
    3
    2
    1
        Serious TEAE
    4
    6
    7
    5
    6
        Grade >=3 Serious TEAE
    4
    6
    6
    4
    6
        Treatment-Related Serious TEAE
    0
    2
    4
    2
    3
        Ibrutinib-Related Serious TEAE
    0
    2
    4
    2
    3
        Lenalidomide-Related Serious TEAE
    0
    2
    4
    2
    3
        Rituximab-Related Serious TEAE
    0
    2
    2
    1
    0
        Fatal TEAE
    0
    2
    2
    1
    1
    No statistical analyses for this end point

    Primary: Phase 2: Overall Response Rate (ORR)

    Close Top of page
    End point title
    Phase 2: Overall Response Rate (ORR) [4] [5]
    End point description
    The ORR was defined as the percentage of participants who achieve either a partial response (PR) or complete response (CR), according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (see Cheson, 2014 for detailed criteria), as assessed by the investigator in response-evaluable population. The 95% confidence interval (CI) was calculated using the exact method. Response-Evaluable Population: participants who had measurable disease at baseline and had at least 1 adequate post-treatment disease assessment by the investigator.
    End point type
    Primary
    End point timeframe
    Estimated median time on study in Phase 2 was 35.0 months.
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Descriptive statistics are presented per protocol.
    [5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Phase 1 data are presented as a separate endpoint.
    End point values
    Phase 2: Enrolled at Lenalidomide Dose 20 mg Phase 2: Enrolled at Lenalidomide Dose 25 mg Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg
    Number of subjects analysed
    53
    32
    85
    Units: percentage of participants
        number (confidence interval 95%)
    52.8 (38.6 to 66.7)
    43.8 (26.4 to 62.3)
    49.4 (38.4 to 60.5)
    No statistical analyses for this end point

    Secondary: Phase 1b: ORR

    Close Top of page
    End point title
    Phase 1b: ORR [6]
    End point description
    The ORR was defined as the percentage of participants who achieve either a PR or CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma (Cheson 2007), as assessed by the Investigator in response-evaluable population, where CR=disappearance of all evidence of disease and PR=regression of measurable disease and no new sites. The 95% CI was calculated using the exact method. Response-Evaluable Population: participants who had measurable disease at baseline and had at least 1 adequate post-treatment disease assessment by the investigator.
    End point type
    Secondary
    End point timeframe
    Estimated median time on study in Phase 1b was 59.6 months.
    Notes
    [6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Phase 2 data are presented as a separate endpoint.
    End point values
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) All Phase 1b Participants
    Number of subjects analysed
    9
    7
    7
    9
    8
    40
    Units: percentage of participants
        number (confidence interval 95%)
    44.4 (13.7 to 78.8)
    0 (0 to 41.0)
    71.4 (29.0 to 96.3)
    22.2 (2.8 to 60.0)
    75.0 (34.9 to 96.8)
    42.5 (27.0 to 59.1)
    No statistical analyses for this end point

    Secondary: Phase 1b: Complete Response (CR) Rate

    Close Top of page
    End point title
    Phase 1b: Complete Response (CR) Rate [7]
    End point description
    The CR rate was defined as the percentage of participants who achieve a CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma (Cheson 2007), as assessed by the Investigator in response-evaluable population, where CR=disappearance of all evidence of disease, as assessed by the Investigator. Response-Evaluable Population: participants who had measurable disease at baseline and had at least 1 adequate post-treatment disease assessment by the investigator.
    End point type
    Secondary
    End point timeframe
    Estimated median time on Phase 1b study was 59.6 months.
    Notes
    [7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Phase 2 data are presented as a separate endpoint.
    End point values
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) All Phase 1b Participants
    Number of subjects analysed
    9
    7
    7
    9
    8
    40
    Units: percentage of participants
        number (not applicable)
    33.3
    0
    42.9
    11.1
    50.0
    27.5
    No statistical analyses for this end point

    Secondary: Phase 2: CR Rate

    Close Top of page
    End point title
    Phase 2: CR Rate [8]
    End point description
    The CR rate was defined as the percentage of participants who achieve a CR, according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (see Cheson, 2014 for detailed criteria), as assessed by the Investigator in response-evaluable population. Response-Evaluable Population: participants who had measurable disease at baseline and had at least 1 adequate post-treatment disease assessment by the investigator.
    End point type
    Secondary
    End point timeframe
    Estimated median time on study in Phase 2 was 35.0 months.
    Notes
    [8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Phase 1 data are presented as a separate endpoint.
    End point values
    Phase 2: Enrolled at Lenalidomide Dose 20 mg Phase 2: Enrolled at Lenalidomide Dose 25 mg Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg
    Number of subjects analysed
    53
    32
    89
    Units: percentage of participants
        number (not applicable)
    32.1
    21.9
    28.0
    No statistical analyses for this end point

    Secondary: Phase 2: Duration of Response (DOR)

    Close Top of page
    End point title
    Phase 2: Duration of Response (DOR) [9]
    End point description
    DOR is defined as the time from the date of the first documented response (CR or PR) to the first documented evidence of disease progression (PD) according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014) or death from any cause. For participants who had achieved an overall response but did not die or progress at the time of analysis, DOR was censored on the date of the last adequate post-baseline disease assessment, or on the date of the first occurrence of response (CR or PR) if there was no disease assessment afterwards. 2-sided 95% CI is estimated by Kaplan-Meier method. All-Treated Analysis Population (Phase 2): participants who received any dose of study drug(s). Participants who achieved Overall Response.
    End point type
    Secondary
    End point timeframe
    Estimated median time on study in Phase 2 was 35.0 months.
    Notes
    [9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Per protocol, this endpoint addresses Phase 2 only.
    End point values
    Phase 2: Enrolled at Lenalidomide Dose 20 mg Phase 2: Enrolled at Lenalidomide Dose 25 mg Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg
    Number of subjects analysed
    28 [10]
    14
    42 [11]
    Units: months
        median (confidence interval 95%)
    38.3 (3.7 to 99999)
    28.6 (2.8 to 28.6)
    38.3 (9.5 to 99999)
    Notes
    [10] - 99999=The 95% Confidence limit cannot be estimated.
    [11] - 99999=The 95% Confidence limit cannot be estimated.
    No statistical analyses for this end point

    Secondary: Phase 2: Progression Free Survival (PFS)

    Close Top of page
    End point title
    Phase 2: Progression Free Survival (PFS) [12]
    End point description
    PFS is defined as the time from the date of the first dose of study drug to confirmed PD according to the Revised International Working Group Response Criteria for Malignant Lymphoma or Lugano Classification (Cheson 2014) or death from any cause, whichever occurred first. For participants without disease progression or death, PFS data was censored at the date of the last tumor assessment. 2 sided 95% CI is estimated by Kaplan-Meier method. All-Treated Analysis Population (Phase 2): participants who received any dose of study drug(s).
    End point type
    Secondary
    End point timeframe
    Estimated median time on study in Phase 2 was 35.0 months.
    Notes
    [12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Per protocol, this endpoint addresses Phase 2 only.
    End point values
    Phase 2: Enrolled at Lenalidomide Dose 20 mg Phase 2: Enrolled at Lenalidomide Dose 25 mg Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg
    Number of subjects analysed
    55
    34
    89
    Units: months
        median (confidence interval 95%)
    5.4 (3.4 to 11.3)
    4.7 (2.6 to 24.8)
    5.4 (3.4 to 6.3)
    No statistical analyses for this end point

    Secondary: Phase 2: Overall Survival (OS)

    Close Top of page
    End point title
    Phase 2: Overall Survival (OS) [13]
    End point description
    OS is defined as the time from the date of the first dose of study drug to the date of death due to any cause. For participants not known to have died at or prior to the database lock date, OS data was censored at the date last known alive. Participants who withdrew consent prior to study closure were censored on the date of the consent withdrawal. 2-sided 95% CI was estimated by Kaplan-Meier method. All-Treated Analysis Population (Phase 2): participants who received any dose of study drug(s).
    End point type
    Secondary
    End point timeframe
    Estimated median time on study in Phase 2 was 35.0 months.
    Notes
    [13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Per protocol, this endpoint addresses Phase 2 only.
    End point values
    Phase 2: Enrolled at Lenalidomide Dose 20 mg Phase 2: Enrolled at Lenalidomide Dose 25 mg Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg
    Number of subjects analysed
    55
    34 [14]
    89
    Units: months
        median (confidence interval 95%)
    14.7 (9.7 to 32.8)
    11.6 (5.7 to 99999)
    14.2 (9.7 to 28.1)
    Notes
    [14] - 99999=The 95% Confidence limit cannot be estimated.
    No statistical analyses for this end point

    Secondary: Phase 2: Number of Participants With TEAEs, Serious TEAEs, and Discontinuations Due to TEAEs

    Close Top of page
    End point title
    Phase 2: Number of Participants With TEAEs, Serious TEAEs, and Discontinuations Due to TEAEs [15]
    End point description
    An AE is any untoward medical occurrence, which does not necessarily have a causal relationship with treatment. A serious AE is any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization > 24 hours or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; is an important medical event. AEs that started or worsened during the treatment-emergent period and all possibly related or related AEs were considered TEAEs. Related events were those that were considered possibly related or related to study drug per investigator's judgment. Events were graded per the national Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.03: Grade 1=mild; grade 2=moderate; grade 3=severe; grade 4=life-threatening; grade 5=death. All-Treated Analysis Population (Phase 2): participants who received any dose of study drug(s).
    End point type
    Secondary
    End point timeframe
    From first dose of study drug up to 30 days after last dose of study drug. Phase 2 median duration of ibrutinib exposure=4.9 months; median duration of lenalidomide exposure=4.7 months; median total number of doses of rituximab received=5.0.
    Notes
    [15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: Phase 1 data are presented as a separate endpoint.
    End point values
    Phase 2: Enrolled at Lenalidomide Dose 20 mg Phase 2: Enrolled at Lenalidomide Dose 25 mg Phase 2 Total: Enrolled at Lenalidomide Dose 20 or 25 mg
    Number of subjects analysed
    55
    34
    89
    Units: participants
        TEAE
    55
    34
    89
        Grade >=3 TEAE
    51
    30
    81
        Study Drug-Related TEAE
    52
    33
    85
        Grade >=3 Study Drug-Related TEAE
    41
    25
    66
        Ibrutinib-Related TEAE
    50
    32
    82
        Grade >=3 Ibrutinib-Related TEAE
    36
    24
    60
        Lenalidomide-Related TEAE
    51
    32
    83
        Grade >=3 Lenalidomide-Related TEAE
    40
    25
    65
        Rituximab-Related TEAE
    37
    25
    62
        Grade >= 3 Rituximab-Related TEAE
    18
    13
    31
        TEAE Leading to Dose Reduction of Any Study Drug
    23
    14
    37
        TEAE Leading to Dose Reduction of Ibrutinib
    12
    9
    21
        TEAE Leading to Dose Reduction of Lenalidomide
    21
    14
    35
        TEAE Leading to Dose Delay of Any Study Drug
    40
    29
    69
        TEAE Leading to Dose Delay of Ibrutinib
    38
    28
    66
        TEAE Leading to Dose Delay of Lenalidomide
    37
    26
    63
        TEAE Leading to Dose Delay of Rituximab
    10
    6
    16
        TEAE Leading to Discontinuation of Any Study Drug
    11
    7
    18
        TEAE Leading to Discontinuation of Ibrutinib Dose
    11
    5
    16
        TEAE Leading to Discontinuation of Lenalid. Dose
    11
    7
    18
        TEAE Leading to Discontinuation of Rituximab Dose
    6
    4
    10
        Serious TEAE
    32
    25
    57
        Grade >=3 Serious TEAE
    29
    21
    50
        Treatment-Related Serious TEAE
    16
    12
    28
        Ibrutinib-Related Serious TEAE
    14
    12
    26
        Lenalidomide-Related Serious TEAE
    16
    10
    26
        Rituximab-Related Serious TEAE
    4
    5
    9
        Fatal TEAE
    8
    4
    12
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From first dose of study drug up to 30 days after last dose of study drug. Phase 1b median duration of ibrutinib exposure was 4.4 months; median duration of lenalidomide exposure was 4.4 months; median total number of doses of rituximab received was 4.0
    Adverse event reporting additional description
    Phase 2 median duration of ibrutinib exposure was 4.9 months; median duration of lenalidomide exposure was 4.7 months; median total number of doses of rituximab received was 5.0.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    23.1
    Reporting groups
    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1)
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1)
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 10 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+)
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 15 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2)
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3)
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 2: Enrolled at Lenalidomide Dose 20 mg
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 20 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Reporting group title
    Phase 2: Enrolled at Lenalidomide Dose 25 mg
    Reporting group description
    Ibrutinib 560 mg administered PO QD beginning Cycle 1 Day 1 until disease progression or unacceptable toxicity. Lenalidomide 25 mg administered PO QD on Days 1-21 of each 28-day cycle until disease progression or unacceptable toxicity. Rituximab 375 mg/m^2 administered IV on Day 1 of each 28-day cycle for 6 cycles.

    Serious adverse events
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) Phase 2: Enrolled at Lenalidomide Dose 20 mg Phase 2: Enrolled at Lenalidomide Dose 25 mg
    Total subjects affected by serious adverse events
         subjects affected / exposed
    4 / 12 (33.33%)
    6 / 7 (85.71%)
    7 / 9 (77.78%)
    5 / 9 (55.56%)
    6 / 8 (75.00%)
    32 / 55 (58.18%)
    25 / 34 (73.53%)
         number of deaths (all causes)
    7
    7
    5
    7
    5
    33
    22
         number of deaths resulting from adverse events
    0
    2
    2
    1
    1
    8
    4
    Vascular disorders
    DEEP VEIN THROMBOSIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HYPOTENSION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    ACUTE MYELOID LEUKAEMIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BASAL CELL CARCINOMA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BOWEN'S DISEASE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DIFFUSE LARGE B-CELL LYMPHOMA
         subjects affected / exposed
    0 / 12 (0.00%)
    2 / 7 (28.57%)
    1 / 9 (11.11%)
    2 / 9 (22.22%)
    1 / 8 (12.50%)
    5 / 55 (9.09%)
    3 / 34 (8.82%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 2
    0 / 1
    0 / 5
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    0 / 2
    0 / 1
    0 / 1
    0 / 1
    0 / 4
    0 / 3
    INTRADUCTAL PROLIFERATIVE BREAST LESION
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LUNG NEOPLASM MALIGNANT
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MYELODYSPLASTIC SYNDROME
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    OCULAR LYMPHOMA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SQUAMOUS CELL CARCINOMA OF SKIN
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    ASTHENIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CATHETER SITE PAIN
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CHILLS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FATIGUE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NON-CARDIAC CHEST PAIN
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    OEDEMA PERIPHERAL
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PYREXIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    5 / 55 (9.09%)
    4 / 34 (11.76%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    1 / 1
    0 / 0
    2 / 5
    2 / 4
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Psychiatric disorders
    ANXIETY
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CONFUSIONAL STATE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DELIRIUM
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SUICIDAL IDEATION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Reproductive system and breast disorders
    PROSTATIC OBSTRUCTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    VAGINAL HAEMORRHAGE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    FALL
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FEMORAL NECK FRACTURE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FIBULA FRACTURE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HIP FRACTURE
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    UPPER LIMB FRACTURE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Investigations
    NEUTROPHIL COUNT DECREASED
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cardiac disorders
    ATRIAL FIBRILLATION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    2 / 9 (22.22%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    3 / 3
    3 / 4
    1 / 1
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ATRIAL FLUTTER
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CARDIAC ARREST
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    2 / 55 (3.64%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    MYOCARDIAL INFARCTION
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SUPRAVENTRICULAR TACHYCARDIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    ACUTE RESPIRATORY FAILURE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    COUGH
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DYSPNOEA
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    2 / 55 (3.64%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PLEURAL EFFUSION
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PLEURISY
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    RESPIRATORY FAILURE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Blood and lymphatic system disorders
    ANAEMIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    2 / 9 (22.22%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FEBRILE NEUTROPENIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    2 / 9 (22.22%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    2 / 34 (5.88%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    2 / 2
    0 / 0
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HAEMOLYTIC ANAEMIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NEUTROPENIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PANCYTOPENIA
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    DIZZINESS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    EMBOLIC CEREBRAL INFARCTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LOSS OF CONSCIOUSNESS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SYNCOPE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    TRANSIENT ISCHAEMIC ATTACK
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Gastrointestinal disorders
    ABDOMINAL PAIN UPPER
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    COLITIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    DIARRHOEA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    2 / 55 (3.64%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    2 / 2
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GASTRIC HAEMORRHAGE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GASTROINTESTINAL HAEMORRHAGE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    1 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GASTROSPLENIC FISTULA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INCARCERATED INGUINAL HERNIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INTESTINAL OBSTRUCTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NAUSEA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SMALL INTESTINAL OBSTRUCTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    VOMITING
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    2 / 34 (5.88%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    1 / 1
    0 / 0
    1 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    ACUTE KIDNEY INJURY
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HYDRONEPHROSIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    URINARY TRACT OBSTRUCTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    BILE DUCT STENOSIS
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CHOLECYSTITIS CHRONIC
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    GALLBLADDER ENLARGEMENT
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Skin and subcutaneous tissue disorders
    DERMATITIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PURPURA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    RASH MACULO-PAPULAR
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    ARTHRALGIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BACK PAIN
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    2 / 55 (3.64%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MOBILITY DECREASED
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    MUSCULOSKELETAL CHEST PAIN
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SPINAL OSTEOARTHRITIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Metabolism and nutrition disorders
    DEHYDRATION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    1 / 9 (11.11%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 1
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FAILURE TO THRIVE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HYPERCALCAEMIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 2
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HYPONATRAEMIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    TUMOUR LYSIS SYNDROME
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    ACUTE SINUSITIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    BRONCHITIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CANDIDA INFECTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CELLULITIS
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    2 / 8 (25.00%)
    2 / 55 (3.64%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    2 / 3
    0 / 0
    0 / 3
    1 / 2
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    CELLULITIS ORBITAL
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    ESCHERICHIA SEPSIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    FOLLICULITIS
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    HAEMATOMA INFECTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    INFLUENZA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LOWER RESPIRATORY TRACT INFECTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LOWER RESPIRATORY TRACT INFECTION BACTERIAL
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    LYMPHANGITIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    NEUTROPENIC SEPSIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PARAINFLUENZAE VIRUS INFECTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PERITONITIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PNEUMONIA
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    3 / 55 (5.45%)
    2 / 34 (5.88%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 2
    0 / 0
    0 / 0
    1 / 3
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 2
    1 / 1
    PNEUMONIA BACTERIAL
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    PNEUMONIA VIRAL
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SALMONELLA BACTERAEMIA
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    SEPSIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    1 / 1
    0 / 0
    SEPTIC SHOCK
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    UPPER RESPIRATORY TRACT INFECTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    URINARY TRACT INFECTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    3 / 55 (5.45%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    2 / 4
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    WOUND SEPSIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1) Phase 1b: Enrolled at Lenalidomide Dose 10 mg (Dose Level -1) Phase 1b: Enrolled at Lenalidomide Dose 15 mg (Dose Level 1+) Phase 1b: Enrolled at Lenalidomide Dose 20 mg (Dose Level 2) Phase 1b: Enrolled at Lenalidomide Dose 25 mg (Dose Level 3) Phase 2: Enrolled at Lenalidomide Dose 20 mg Phase 2: Enrolled at Lenalidomide Dose 25 mg
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    12 / 12 (100.00%)
    7 / 7 (100.00%)
    9 / 9 (100.00%)
    9 / 9 (100.00%)
    8 / 8 (100.00%)
    54 / 55 (98.18%)
    34 / 34 (100.00%)
    Vascular disorders
    DEEP VEIN THROMBOSIS
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    0
    HOT FLUSH
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    0
    HYPERTENSION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    2 / 9 (22.22%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    5 / 34 (14.71%)
         occurrences all number
    0
    0
    2
    0
    3
    21
    15
    HYPOTENSION
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    3 / 55 (5.45%)
    3 / 34 (8.82%)
         occurrences all number
    2
    0
    2
    1
    0
    3
    3
    PERIPHERAL COLDNESS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    VARICOSE VEIN
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    CANCER PAIN
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    1
    0
    0
    LIPOMA
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    1
    0
    0
    0
    0
    TUMOUR PAIN
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    Immune system disorders
    DRUG HYPERSENSITIVITY
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    0
    HYPERSENSITIVITY
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    2
    HYPOGAMMAGLOBULINAEMIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    3 / 55 (5.45%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    0
    SEASONAL ALLERGY
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    2 / 8 (25.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    0
    Social circumstances
    PHYSICAL ASSAULT
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    General disorders and administration site conditions
    ADVERSE DRUG REACTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    ASTHENIA
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    2 / 9 (22.22%)
    0 / 9 (0.00%)
    2 / 8 (25.00%)
    1 / 55 (1.82%)
    4 / 34 (11.76%)
         occurrences all number
    1
    0
    2
    0
    2
    2
    4
    CHEST DISCOMFORT
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    2 / 9 (22.22%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    1
    0
    CHEST PAIN
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    1
    0
    0
    2
    2
    CHILLS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    2 / 9 (22.22%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    3
    0
    0
    1
    1
    FACE OEDEMA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    FATIGUE
         subjects affected / exposed
    6 / 12 (50.00%)
    3 / 7 (42.86%)
    5 / 9 (55.56%)
    2 / 9 (22.22%)
    3 / 8 (37.50%)
    22 / 55 (40.00%)
    16 / 34 (47.06%)
         occurrences all number
    8
    3
    9
    3
    4
    34
    22
    GAIT DISTURBANCE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    1 / 9 (11.11%)
    1 / 8 (12.50%)
    2 / 55 (3.64%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    1
    1
    2
    0
    INFLUENZA LIKE ILLNESS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    3 / 55 (5.45%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    2
    INFUSION SITE EXTRAVASATION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    INFUSION SITE SWELLING
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    INJECTION SITE PAIN
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    MALAISE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    3 / 55 (5.45%)
    3 / 34 (8.82%)
         occurrences all number
    0
    0
    1
    0
    4
    3
    3
    NODULE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    OEDEMA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    2 / 55 (3.64%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    2
    0
    OEDEMA PERIPHERAL
         subjects affected / exposed
    2 / 12 (16.67%)
    1 / 7 (14.29%)
    3 / 9 (33.33%)
    3 / 9 (33.33%)
    4 / 8 (50.00%)
    21 / 55 (38.18%)
    8 / 34 (23.53%)
         occurrences all number
    2
    1
    3
    3
    5
    30
    10
    PAIN
         subjects affected / exposed
    1 / 12 (8.33%)
    2 / 7 (28.57%)
    2 / 9 (22.22%)
    0 / 9 (0.00%)
    3 / 8 (37.50%)
    2 / 55 (3.64%)
    2 / 34 (5.88%)
         occurrences all number
    1
    2
    2
    0
    3
    2
    2
    PERIPHERAL SWELLING
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    4 / 55 (7.27%)
    4 / 34 (11.76%)
         occurrences all number
    1
    0
    0
    0
    0
    5
    4
    PYREXIA
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    2 / 9 (22.22%)
    0 / 9 (0.00%)
    3 / 8 (37.50%)
    2 / 55 (3.64%)
    3 / 34 (8.82%)
         occurrences all number
    0
    2
    4
    0
    3
    2
    3
    VESSEL PUNCTURE SITE BRUISE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    Psychiatric disorders
    ANXIETY
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    3 / 55 (5.45%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    2
    CONFUSIONAL STATE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    2 / 9 (22.22%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    1
    0
    DEPRESSION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    2
    DISORIENTATION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    INSOMNIA
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    5 / 55 (9.09%)
    2 / 34 (5.88%)
         occurrences all number
    1
    0
    1
    0
    1
    5
    2
    IRRITABILITY
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    MENTAL STATUS CHANGES
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    0
    STRESS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    Reproductive system and breast disorders
    GENITAL RASH
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    OEDEMA GENITAL
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    VAGINAL HAEMORRHAGE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    2
    Injury, poisoning and procedural complications
    CONTUSION
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    6 / 55 (10.91%)
    5 / 34 (14.71%)
         occurrences all number
    3
    0
    1
    0
    1
    7
    8
    EYE CONTUSION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    1
    1
    0
    0
    FALL
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    3 / 55 (5.45%)
    4 / 34 (11.76%)
         occurrences all number
    4
    0
    0
    0
    0
    3
    4
    IMPACTED FRACTURE
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    INFUSION RELATED REACTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    3 / 55 (5.45%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    1
    3
    1
    LIMB INJURY
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    1
    LUMBAR VERTEBRAL FRACTURE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    MOUTH INJURY
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    1
    0
    NAIL INJURY
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    POST PROCEDURAL HAEMATOMA
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    PROCEDURAL PAIN
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    2 / 8 (25.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    1
    0
    RIB FRACTURE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    SCRATCH
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    SKIN ABRASION
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    0
    SKIN LACERATION
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    3 / 55 (5.45%)
    1 / 34 (2.94%)
         occurrences all number
    3
    0
    0
    0
    1
    3
    1
    SPINAL COMPRESSION FRACTURE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    1
    WOUND
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    5
    0
    1
    Investigations
    ALANINE AMINOTRANSFERASE INCREASED
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    1 / 9 (11.11%)
    1 / 8 (12.50%)
    2 / 55 (3.64%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    2
    1
    2
    3
    5
    ASPARTATE AMINOTRANSFERASE INCREASED
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    1 / 9 (11.11%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    1
    1
    1
    1
    3
    BLOOD ALKALINE PHOSPHATASE INCREASED
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    2 / 55 (3.64%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    3
    0
    BLOOD BILIRUBIN INCREASED
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    2 / 55 (3.64%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    1
    3
    1
    BLOOD CREATINE INCREASED
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    BLOOD CREATININE INCREASED
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    2 / 55 (3.64%)
    0 / 34 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    8
    0
    BLOOD LACTATE DEHYDROGENASE INCREASED
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    1
    BLOOD URINE PRESENT
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    BODY TEMPERATURE FLUCTUATION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    CARDIAC MURMUR
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    3 / 55 (5.45%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    3
    0
    0
    4
    0
    CREATININE RENAL CLEARANCE DECREASED
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    1 / 9 (11.11%)
    3 / 8 (37.50%)
    6 / 55 (10.91%)
    6 / 34 (17.65%)
         occurrences all number
    2
    0
    2
    1
    3
    11
    12
    LYMPHOCYTE COUNT DECREASED
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    4
    2
    0
    NEUTROPHIL COUNT DECREASED
         subjects affected / exposed
    0 / 12 (0.00%)
    2 / 7 (28.57%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    7 / 55 (12.73%)
    2 / 34 (5.88%)
         occurrences all number
    0
    2
    0
    0
    7
    53
    2
    PLATELET COUNT DECREASED
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    5 / 55 (9.09%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    0
    0
    1
    14
    5
    STAPHYLOCOCCUS TEST POSITIVE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    TRANSAMINASES INCREASED
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    2
    2
    0
    1
    0
    VITAMIN D DECREASED
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    WEIGHT DECREASED
         subjects affected / exposed
    2 / 12 (16.67%)
    2 / 7 (28.57%)
    2 / 9 (22.22%)
    1 / 9 (11.11%)
    3 / 8 (37.50%)
    8 / 55 (14.55%)
    4 / 34 (11.76%)
         occurrences all number
    2
    2
    2
    1
    3
    11
    8
    WHITE BLOOD CELL COUNT DECREASED
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    1
    0
    0
    4
    0
    0
    Cardiac disorders
    ATRIAL FIBRILLATION
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    2 / 34 (5.88%)
         occurrences all number
    0
    1
    1
    0
    0
    2
    2
    PALPITATIONS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    4 / 34 (11.76%)
         occurrences all number
    0
    0
    1
    0
    2
    1
    4
    SINUS BRADYCARDIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    2 / 55 (3.64%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    1
    2
    1
    SINUS TACHYCARDIA
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    2 / 9 (22.22%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences all number
    0
    1
    2
    0
    0
    0
    1
    TACHYCARDIA
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    1
    0
    Respiratory, thoracic and mediastinal disorders
    ALLERGIC SINUSITIS
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    APHONIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    COUGH
         subjects affected / exposed
    3 / 12 (25.00%)
    0 / 7 (0.00%)
    2 / 9 (22.22%)
    0 / 9 (0.00%)
    3 / 8 (37.50%)
    18 / 55 (32.73%)
    13 / 34 (38.24%)
         occurrences all number
    3
    0
    4
    0
    5
    27
    19
    DYSPHONIA
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    2 / 9 (22.22%)
    1 / 8 (12.50%)
    2 / 55 (3.64%)
    3 / 34 (8.82%)
         occurrences all number
    0
    1
    0
    2
    1
    2
    3
    DYSPNOEA
         subjects affected / exposed
    2 / 12 (16.67%)
    1 / 7 (14.29%)
    1 / 9 (11.11%)
    3 / 9 (33.33%)
    3 / 8 (37.50%)
    17 / 55 (30.91%)
    7 / 34 (20.59%)
         occurrences all number
    2
    3
    2
    3
    3
    23
    9
    DYSPNOEA EXERTIONAL
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    5 / 55 (9.09%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    1
    0
    0
    7
    0
    EPISTAXIS
         subjects affected / exposed
    2 / 12 (16.67%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    2 / 9 (22.22%)
    0 / 8 (0.00%)
    5 / 55 (9.09%)
    3 / 34 (8.82%)
         occurrences all number
    4
    1
    0
    2
    0
    7
    4
    HICCUPS
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    1
    0
    0
    0
    0
    HYPOXIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    LUNG DISORDER
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    NASAL CONGESTION
         subjects affected / exposed
    2 / 12 (16.67%)
    1 / 7 (14.29%)
    1 / 9 (11.11%)
    1 / 9 (11.11%)
    1 / 8 (12.50%)
    4 / 55 (7.27%)
    5 / 34 (14.71%)
         occurrences all number
    2
    1
    1
    1
    1
    5
    5
    NASAL DRYNESS
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    1 / 34 (2.94%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    1
    NASAL SEPTUM PERFORATION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    OROPHARYNGEAL PAIN
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    1 / 9 (11.11%)
    1 / 8 (12.50%)
    6 / 55 (10.91%)
    1 / 34 (2.94%)
         occurrences all number
    1
    0
    1
    1
    1
    9
    2
    PARANASAL SINUS HYPERSECRETION
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    1
    0
    PLEURAL EFFUSION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    2 / 8 (25.00%)
    4 / 55 (7.27%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    4
    7
    0
    PNEUMONITIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    3 / 55 (5.45%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    0
    PRODUCTIVE COUGH
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    1 / 9 (11.11%)
    1 / 9 (11.11%)
    3 / 8 (37.50%)
    4 / 55 (7.27%)
    5 / 34 (14.71%)
         occurrences all number
    0
    1
    1
    1
    3
    6
    5
    RESPIRATORY DISORDER
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    RESPIRATORY TRACT CONGESTION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    2 / 9 (22.22%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    2
    0
    1
    0
    0
    RHINITIS ALLERGIC
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences all number
    0
    1
    0
    1
    0
    1
    1
    RHINORRHOEA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    2 / 9 (22.22%)
    0 / 9 (0.00%)
    2 / 8 (25.00%)
    4 / 55 (7.27%)
    3 / 34 (8.82%)
         occurrences all number
    0
    0
    3
    0
    4
    4
    4
    SINUS CONGESTION
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    2
    0
    1
    0
    0
    UPPER RESPIRATORY TRACT CONGESTION
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    1
    0
    WHEEZING
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    2 / 55 (3.64%)
    0 / 34 (0.00%)
         occurrences all number
    0
    1
    0
    0
    1
    2
    0
    YAWNING
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    Blood and lymphatic system disorders
    ANAEMIA
         subjects affected / exposed
    4 / 12 (33.33%)
    0 / 7 (0.00%)
    3 / 9 (33.33%)
    3 / 9 (33.33%)
    2 / 8 (25.00%)
    17 / 55 (30.91%)
    11 / 34 (32.35%)
         occurrences all number
    6
    0
    6
    22
    6
    88
    16
    FEBRILE NEUTROPENIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    0
    INCREASED TENDENCY TO BRUISE
         subjects affected / exposed
    2 / 12 (16.67%)
    1 / 7 (14.29%)
    2 / 9 (22.22%)
    0 / 9 (0.00%)
    2 / 8 (25.00%)
    8 / 55 (14.55%)
    5 / 34 (14.71%)
         occurrences all number
    3
    1
    3
    0
    2
    13
    6
    LEUKOCYTOSIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    LEUKOPENIA
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    1 / 8 (12.50%)
    3 / 55 (5.45%)
    3 / 34 (8.82%)
         occurrences all number
    7
    0
    0
    4
    2
    35
    6
    LYMPHADENOPATHY
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    LYMPHOCYTOSIS
         subjects affected / exposed
    0 / 12 (0.00%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    LYMPHOPENIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    2 / 9 (22.22%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    2
    2
    0
    0
    0
    NEUTROPENIA
         subjects affected / exposed
    5 / 12 (41.67%)
    0 / 7 (0.00%)
    6 / 9 (66.67%)
    3 / 9 (33.33%)
    5 / 8 (62.50%)
    25 / 55 (45.45%)
    14 / 34 (41.18%)
         occurrences all number
    13
    0
    46
    22
    41
    126
    68
    PANCYTOPENIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    1
    0
    0
    SPONTANEOUS HAEMATOMA
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    2 / 55 (3.64%)
    1 / 34 (2.94%)
         occurrences all number
    1
    0
    1
    0
    0
    2
    1
    THROMBOCYTOPENIA
         subjects affected / exposed
    4 / 12 (33.33%)
    2 / 7 (28.57%)
    4 / 9 (44.44%)
    4 / 9 (44.44%)
    3 / 8 (37.50%)
    11 / 55 (20.00%)
    10 / 34 (29.41%)
         occurrences all number
    8
    5
    9
    21
    10
    61
    36
    Nervous system disorders
    APHASIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    2
    0
    0
    ATAXIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    BALANCE DISORDER
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    DIZZINESS
         subjects affected / exposed
    4 / 12 (33.33%)
    0 / 7 (0.00%)
    2 / 9 (22.22%)
    3 / 9 (33.33%)
    1 / 8 (12.50%)
    11 / 55 (20.00%)
    7 / 34 (20.59%)
         occurrences all number
    5
    0
    2
    5
    2
    16
    7
    DIZZINESS POSTURAL
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    2 / 55 (3.64%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    2
    0
    DYSARTHRIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    DYSGEUSIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    4 / 55 (7.27%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    4
    0
    HEAD DISCOMFORT
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    HEADACHE
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 7 (0.00%)
    3 / 9 (33.33%)
    1 / 9 (11.11%)
    3 / 8 (37.50%)
    3 / 55 (5.45%)
    4 / 34 (11.76%)
         occurrences all number
    2
    0
    3
    1
    3
    4
    6
    HYPOAESTHESIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    2 / 55 (3.64%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    1
    0
    0
    2
    2
    PARAESTHESIA
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    5 / 55 (9.09%)
    2 / 34 (5.88%)
         occurrences all number
    1
    1
    0
    0
    1
    5
    2
    PARKINSON'S DISEASE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    PERIPHERAL MOTOR NEUROPATHY
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    3 / 55 (5.45%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    6
    0
    PERIPHERAL SENSORIMOTOR NEUROPATHY
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    3 / 55 (5.45%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    0
    0
    3
    1
    PERIPHERAL SENSORY NEUROPATHY
         subjects affected / exposed
    1 / 12 (8.33%)
    1 / 7 (14.29%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    1 / 8 (12.50%)
    11 / 55 (20.00%)
    7 / 34 (20.59%)
         occurrences all number
    1
    1
    0
    1
    1
    20
    14
    PRESYNCOPE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    1 / 34 (2.94%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    1
    RESTLESS LEGS SYNDROME
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    SCIATICA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    2 / 55 (3.64%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    1
    2
    0
    SPEECH DISORDER
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    SYNCOPE
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    1
    0
    0
    2
    2
    TREMOR
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    2 / 9 (22.22%)
    1 / 8 (12.50%)
    4 / 55 (7.27%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    2
    1
    4
    0
    Eye disorders
    CATARACT
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    2 / 55 (3.64%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    3
    0
    CHALAZION
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    DRY AGE-RELATED MACULAR DEGENERATION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    DRY EYE
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    6 / 55 (10.91%)
    6 / 34 (17.65%)
         occurrences all number
    1
    0
    0
    1
    0
    7
    8
    EXOPHTHALMOS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    1
    0
    0
    EYE OEDEMA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    EYE PAIN
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    1
    1
    0
    EYE PRURITUS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    3 / 34 (8.82%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    3
    LACRIMATION INCREASED
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    4 / 55 (7.27%)
    2 / 34 (5.88%)
         occurrences all number
    1
    0
    0
    0
    0
    4
    2
    METAMORPHOPSIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    OCULAR HYPERAEMIA
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    OPTIC NERVE COMPRESSION
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    PERIORBITAL SWELLING
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    PHOTOPHOBIA
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    TRICHIASIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    VISION BLURRED
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    1 / 9 (11.11%)
    1 / 8 (12.50%)
    2 / 55 (3.64%)
    3 / 34 (8.82%)
         occurrences all number
    0
    0
    1
    1
    1
    2
    3
    VISUAL ACUITY REDUCED
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    VISUAL IMPAIRMENT
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    3 / 55 (5.45%)
    1 / 34 (2.94%)
         occurrences all number
    1
    0
    0
    0
    0
    3
    1
    Ear and labyrinth disorders
    DEAFNESS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    1
    0
    EAR PAIN
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    2 / 9 (22.22%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    1 / 55 (1.82%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    2
    0
    1
    1
    3
    HYPOACUSIS
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    1 / 55 (1.82%)
    2 / 34 (5.88%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    2
    VERTIGO
         subjects affected / exposed
    1 / 12 (8.33%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    0 / 9 (0.00%)
    1 / 8 (12.50%)
    0 / 55 (0.00%)
    2 / 34 (5.88%)
         occurrences all number
    1
    0
    0
    0
    1
    0
    2
    Gastrointestinal disorders
    ABDOMINAL DISCOMFORT
         subjects affected / exposed
    0 / 12 (0.00%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    0 / 9 (0.00%)
    0 / 8 (0.00%)
    0 / 55 (0.00%)
    0 / 34 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    ABDOMINAL DISTENSION
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 7 (0.00%)
    1 / 9 (11.11%)
    1 / 9 (11.11%)
    1 / 8 (12.50%)
    2 / 55 (3.64%)
    0 / 34 (0.00%)
         occurrences all number
    2
    0
    1
    1
    1
    2
    0
    ABDOMINAL PAIN
         subjects affected / exposed
    2 / 12 (16.67%)
    2 / 7 (28.57%)
    0 / 9 (0.00%)
    3 / 9 (33.33%)
    2 / 8 (25.00%)
    9 / 55 (16.36%)
    7 / 34 (20.59%)
         occurrences all number
    2
    2
    0
    3
    2
    11
    10
    ABDOMINAL PAIN UPPER
         subjects affected / exposed
    2 / 12 (16.67%)
    0 / 7 (0.00%)
    0 / 9 (0.00%)
    1 / 9 (11.11%)
    0 / 8 (0.00%)
    3 / 55 (5.45%)
    1 / 34 (2.94%)
         occurrences all number
    2
    0
    0
    1
    0
    4